KLK3 and prostate carcinoma: The benefit of genetically adjusting PSA was most evident for detection of aggressive prostate cancer, defined as Gleason ≥7, PSA ≥ 10 ng ml−1, T3–T4 stage and/or distant or nodal metastases.